TY - JOUR
T1 - Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma
AU - Chen, Olivia M.
AU - Kim, Keemberly
AU - Steele, Chelsea
AU - Wilmas, Kelly M.
AU - Aboul-Fettouh, Nader
AU - Burns, Carrick
AU - Doan, Hung Quoc
AU - Silapunt, Sirunya
AU - Migden, Michael R.
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022/8
Y1 - 2022/8
N2 - Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, and patient attributes determine the risk level and acceptable treatment options. Surgical options offer histologic confirmation of tumor clearance. Standard excision provides post-treatment histologic assessment, while Mohs micrographic surgery (MMS) provides complete margin assessment intraoperatively. Additional treatment options may be employed in the correct clinical context. Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.
AB - Basal cell carcinoma (BCC), the most common cancer in humans, is a malignant neoplasm of cells derived from the basal layer of the epidermis. Tumor characteristics such as histologic subtype, primary versus recurrent tumor, anatomic location, size, and patient attributes determine the risk level and acceptable treatment options. Surgical options offer histologic confirmation of tumor clearance. Standard excision provides post-treatment histologic assessment, while Mohs micrographic surgery (MMS) provides complete margin assessment intraoperatively. Additional treatment options may be employed in the correct clinical context. Small and low-risk BCCs, broad field cancerization, locally-advanced disease, metastatic disease, cosmetic concerns, or morbidity with surgical approaches raise consideration of other treatment modalities. We review herein a range of treatment approaches and advances in treatments for BCC, including standard excision, MMS, electrodesiccation and curettage, ablative laser treatment, radiation therapy, targeted molecular therapies, topical therapies, field therapies, immunotherapy, and experimental therapies.
KW - basal cell carcinoma
KW - basal cell nevus syndrome
KW - cemiplimab
KW - Gorlin syndrome
KW - immunotherapy
KW - Mohs surgery
KW - sonidegib
KW - vismodegib
UR - http://www.scopus.com/inward/record.url?scp=85136784233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85136784233&partnerID=8YFLogxK
U2 - 10.3390/cancers14153720
DO - 10.3390/cancers14153720
M3 - Review article
C2 - 35954384
AN - SCOPUS:85136784233
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 15
M1 - 3720
ER -